Moderna Therapeutics Inc. expects its messenger RNA Therapeutics platform can reduce the time and expense of producing therapeutic proteins compared with recombinant technologies.

The company delivers modified mRNAs by subcutaneous or intramuscular injection, and the molecules are translated into therapeutic proteins in vivo.